Libo Pharma Corp. (7888)

Overview

Libo Pharma Corp. is a clinical-stage biopharmaceutical company that was established in 2017 and is located in Taipei, Taiwan. The organization is dedicated to the development of innovative therapeutics aimed at fulfilling unmet medical needs across various critical fields, including regenerative medicine, hematology, oncology, and immunology. The company's primary asset, NM-IL-12, is a groundbreaking cytokine immunotherapy intended for treatment in several significant areas such as cutaneous T-cell lymphoma (CTCL), hematopoietic syndrome of acute radiation syndrome (HSARS), and open wound healing. NM-IL-12 has successfully progressed to the end-of-Phase 2 trials and is poised for Phase 3 evaluations in these applications.

By leveraging a federated business model, Libo Pharma outsources a variety of operations to a comprehensive global network of partners while overseeing the entire process from a central management perspective. This strategy allows the company to expedite the development of novel drugs. With a workforce of approximately 20 employees and a strong emphasis on safety, demonstrated in over 200 participants having been dosed, Libo Pharma is focused on advancing protein therapeutics and oral drug delivery systems. Operating within the rapidly evolving biotechnology sector, Libo Pharma is committed to pioneering targeted immunotherapies that make a substantial impact in the pharmaceuticals and biotech industries.

Products and Services

• NM-IL-12

  This first-in-class cytokine immunotherapy is designed to treat multiple serious conditions, with a current focus on cutaneous T-cell lymphoma (CTCL). After achieving successful outcomes in end-of-Phase 2 trials, NM-IL-12 is now positioned for Phase 3 clinical evaluations. In addition to CTCL, NM-IL-12 is also being investigated for its efficacy in treating hematopoietic syndrome of acute radiation syndrome (HSARS) and aiding in open wound healing, showcasing its versatility and potential impact across different medical needs.

• Protein Therapeutics

  Libo Pharma specializes in developing protein therapeutics, which involves creating protein-based drugs designed to treat a variety of diseases. By employing advanced biotechnology techniques, the company harnesses the biological properties of proteins to stimulate targeted therapeutic responses, thereby improving patient outcomes in areas where conventional therapies may not suffice.

• Oral Drug Delivery Platforms

  In addition to protein therapeutics, Libo Pharma is also focused on developing innovative oral drug delivery systems. These platforms are designed to enhance the bioavailability and effectiveness of therapeutic agents, making it easier for patients to adhere to treatment protocols while providing more efficient drug absorption compared to traditional methods.